Weiner GJ - Search Results

1

T cells, particularly activated CD4⁺ cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity.

Wang Z, Chimenti MS, Strouse C, Weiner GJ. Wang Z, et al. Among authors: weiner gj. Cancer Immunol Immunother. 2022 Feb;71(2):237-249. doi: 10.1007/s00262-021-02976-7. Epub 2021 Jun 10. Cancer Immunol Immunother. 2022. PMID: 34110453 Free PMC article.

2

The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.

Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY. Weiner GJ, et al. J Immunol. 1994 Mar 1;152(5):2385-92. J Immunol. 1994. PMID: 8133049

3

T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand.

Wooldridge JE, Dahle CE, Weiner GJ. Wooldridge JE, et al. Among authors: weiner gj. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):174-9. doi: 10.1007/s002620050426. Cancer Immunol Immunother. 1997. PMID: 9435867 Free PMC article.

4

Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.

Link BK, Kostelny SA, Cole MS, Fusselman WP, Tso JY, Weiner GJ. Link BK, et al. Among authors: weiner gj. Int J Cancer. 1998 Jul 17;77(2):251-6. doi: 10.1002/(sici)1097-0215(19980717)77:2<251::aid-ijc14>3.0.co;2-e. Int J Cancer. 1998. PMID: 9650561

5

Monoclonal antibody therapy of B cell lymphoma.

Weiner GJ, Link BK. Weiner GJ, et al. Expert Opin Biol Ther. 2004 Mar;4(3):375-85. doi: 10.1517/14712598.4.3.375. Expert Opin Biol Ther. 2004. PMID: 15006731 Review.

6

CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice.

Saha A, Baral RN, Chatterjee SK, Mohanty K, Pal S, Foon KA, Primus FJ, Krieg AM, Weiner GJ, Bhattacharya-Chatterjee M. Saha A, et al. Among authors: weiner gj. Cancer Immunol Immunother. 2006 May;55(5):515-27. doi: 10.1007/s00262-005-0009-6. Epub 2005 Jul 26. Cancer Immunol Immunother. 2006. PMID: 16044253 Free PMC article.

7

CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells.

Bowles JA, Weiner GJ. Bowles JA, et al. Among authors: weiner gj. J Immunol Methods. 2005 Sep;304(1-2):88-99. doi: 10.1016/j.jim.2005.06.018. J Immunol Methods. 2005. PMID: 16109421

8

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith BJ, Breitmeyer JB, Weiner GJ. Bowles JA, et al. Among authors: weiner gj. Blood. 2006 Oct 15;108(8):2648-54. doi: 10.1182/blood-2006-04-020057. Epub 2006 Jul 6. Blood. 2006. PMID: 16825493 Free PMC article.

9

Monoclonal antibody mechanisms of action in cancer.

Weiner GJ. Weiner GJ. Immunol Res. 2007;39(1-3):271-8. doi: 10.1007/s12026-007-0073-4. Immunol Res. 2007. PMID: 17917071 Review.

10

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

Wang SY, Racila E, Taylor RP, Weiner GJ. Wang SY, et al. Among authors: weiner gj. Blood. 2008 Feb 1;111(3):1456-63. doi: 10.1182/blood-2007-02-074716. Epub 2007 Nov 16. Blood. 2008. PMID: 18024795 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

161 results

Search Page

Filters